Tuberous sclerosis complex (TSC) is a rare monogenic disorder co-diagnosed with high rates of autism and is caused by loss of function mutations in the TSC1 or TSC2 genes. A key pathway hyperactivated in TSC is the mammalian/mechanistic target of rapamycin complex 1 (mTORC1), which regulates cap-dependent mRNA translation. We previously demonstrated that exaggerated cap-dependent translation leads to autism-related phenotypes and increased mRNA translation and protein expression of Neuroligin 1 (Nlgn1) in mice. Inhibition of Nlgn1 expression reversed social behavior deficits in mice with increased cap-dependent translation. Herein, we report elevated translation ofNlgn1mRNA and an increase in its protein expression. Genetic or pharmacological inhibition of Nlgn1 expression inTsc2+/−mice rescued impaired hippocampal mGluR-LTD, contextual discrimination and social behavior deficits inTsc2+/−mice, without correcting mTORC1 hyperactivation. Thus, we demonstrate that reduction of Nlgn1 expression inTsc2+/−mice is a new therapeutic strategy for TSC and potentially other neurodevelopmental disorders.